Stem definition | Drug id | CAS RN |
---|---|---|
anticoagulants, dicoumarol derivatives | 2138 | 435-97-2 |
Dose | Unit | Route |
---|---|---|
3 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.43 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.02 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.57 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 126 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 30, 1957 | FDA | ORGANON USA INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
General physical health deterioration | 257.41 | 25.10 | 173 | 5499 | 142261 | 50457191 |
Product prescribing error | 198.06 | 25.10 | 78 | 5594 | 20883 | 50578569 |
Product monitoring error | 159.76 | 25.10 | 41 | 5631 | 2723 | 50596729 |
Atrial fibrillation | 99.65 | 25.10 | 86 | 5586 | 101659 | 50497793 |
Haematochezia | 92.82 | 25.10 | 57 | 5615 | 39825 | 50559627 |
Anaemia | 86.84 | 25.10 | 123 | 5549 | 252333 | 50347119 |
Haematoma | 79.76 | 25.10 | 47 | 5625 | 30463 | 50568989 |
Cardiac failure | 75.86 | 25.10 | 65 | 5607 | 75975 | 50523477 |
Drug interaction | 75.68 | 25.10 | 102 | 5570 | 199519 | 50399933 |
International normalised ratio increased | 71.81 | 25.10 | 50 | 5622 | 43102 | 50556350 |
Labelled drug-drug interaction medication error | 65.24 | 25.10 | 29 | 5643 | 10448 | 50589004 |
Fall | 62.37 | 25.10 | 124 | 5548 | 334808 | 50264644 |
Bradycardia | 60.05 | 25.10 | 53 | 5619 | 64373 | 50535079 |
Acute kidney injury | 57.04 | 25.10 | 96 | 5576 | 227962 | 50371490 |
Drug ineffective | 55.98 | 25.10 | 12 | 5660 | 819321 | 49780131 |
Device stimulation issue | 54.68 | 25.10 | 9 | 5663 | 59 | 50599393 |
Arrhythmia | 51.87 | 25.10 | 37 | 5635 | 33095 | 50566357 |
Pallor | 51.00 | 25.10 | 32 | 5640 | 23167 | 50576285 |
Painful respiration | 41.76 | 25.10 | 14 | 5658 | 2361 | 50597091 |
Foetal chromosome abnormality | 39.56 | 25.10 | 6 | 5666 | 21 | 50599431 |
Therapeutic drug monitoring analysis not performed | 38.49 | 25.10 | 10 | 5662 | 695 | 50598757 |
Prothrombin time prolonged | 38.14 | 25.10 | 19 | 5653 | 8819 | 50590633 |
Electrocardiogram abnormal | 37.78 | 25.10 | 18 | 5654 | 7587 | 50591865 |
Syncope | 36.45 | 25.10 | 51 | 5621 | 102951 | 50496501 |
Eosinophilic granulomatosis with polyangiitis | 36.27 | 25.10 | 12 | 5660 | 1943 | 50597509 |
Gastrointestinal haemorrhage | 33.21 | 25.10 | 41 | 5631 | 73280 | 50526172 |
Vitamin K deficiency | 33.08 | 25.10 | 8 | 5664 | 415 | 50599037 |
Cerebral haemorrhage | 32.95 | 25.10 | 26 | 5646 | 27026 | 50572426 |
Urogenital haemorrhage | 31.85 | 25.10 | 7 | 5665 | 237 | 50599215 |
Dyspnoea | 31.69 | 25.10 | 133 | 5539 | 547475 | 50051977 |
Dehydration | 31.36 | 25.10 | 59 | 5613 | 152390 | 50447062 |
Pulmonary vein occlusion | 31.09 | 25.10 | 6 | 5666 | 105 | 50599347 |
Dizziness | 30.95 | 25.10 | 97 | 5575 | 346272 | 50253180 |
Systemic infection | 30.64 | 25.10 | 11 | 5661 | 2272 | 50597180 |
Tachycardia | 30.35 | 25.10 | 46 | 5626 | 99717 | 50499735 |
Angina pectoris | 29.41 | 25.10 | 24 | 5648 | 26164 | 50573288 |
Fracture | 29.13 | 25.10 | 20 | 5652 | 16813 | 50582639 |
International normalised ratio decreased | 27.49 | 25.10 | 12 | 5660 | 4136 | 50595316 |
Dysmorphism | 27.43 | 25.10 | 10 | 5662 | 2157 | 50597295 |
Skin haemorrhage | 27.30 | 25.10 | 14 | 5658 | 6904 | 50592548 |
Faecaloma | 26.94 | 25.10 | 14 | 5658 | 7094 | 50592358 |
Hygroma colli | 26.60 | 25.10 | 4 | 5668 | 13 | 50599439 |
Epistaxis | 26.16 | 25.10 | 34 | 5638 | 63920 | 50535532 |
Dandy-Walker syndrome | 25.62 | 25.10 | 5 | 5667 | 93 | 50599359 |
Blood loss anaemia | 25.16 | 25.10 | 14 | 5658 | 8125 | 50591327 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
General physical health deterioration | 155.48 | 21.12 | 164 | 7862 | 102693 | 29463808 |
Product prescribing error | 154.65 | 21.12 | 82 | 7944 | 17894 | 29548607 |
Contraindicated product administered | 89.79 | 21.12 | 58 | 7968 | 18208 | 29548293 |
International normalised ratio abnormal | 75.83 | 21.12 | 29 | 7997 | 2934 | 29563567 |
Intestinal haemorrhage | 71.21 | 21.12 | 28 | 7998 | 3051 | 29563450 |
Product monitoring error | 68.09 | 21.12 | 26 | 8000 | 2619 | 29563882 |
Dizziness | 64.69 | 21.12 | 152 | 7874 | 189532 | 29376969 |
Haematoma | 57.93 | 21.12 | 49 | 7977 | 23163 | 29543338 |
Cardiac failure | 56.33 | 21.12 | 87 | 7939 | 79200 | 29487301 |
International normalised ratio increased | 55.12 | 21.12 | 64 | 7962 | 44308 | 29522193 |
Respiratory tract haemorrhage | 54.24 | 21.12 | 17 | 8009 | 947 | 29565554 |
Dyspnoea | 53.80 | 21.12 | 202 | 7824 | 326530 | 29239971 |
Electrolyte imbalance | 53.42 | 21.12 | 35 | 7991 | 11239 | 29555262 |
Platelet dysfunction | 51.93 | 21.12 | 12 | 8014 | 204 | 29566297 |
Blood glucose fluctuation | 50.68 | 21.12 | 23 | 8003 | 3574 | 29562927 |
Syncope | 49.21 | 21.12 | 83 | 7943 | 81288 | 29485213 |
Oedema peripheral | 47.87 | 21.12 | 94 | 7932 | 103463 | 29463038 |
Drug ineffective | 45.47 | 21.12 | 21 | 8005 | 363149 | 29203352 |
Rectal prolapse | 44.17 | 21.12 | 11 | 8015 | 260 | 29566241 |
Blood glucose abnormal | 43.13 | 21.12 | 23 | 8003 | 5060 | 29561441 |
Intraductal papillary mucinous neoplasm | 41.69 | 21.12 | 11 | 8015 | 329 | 29566172 |
Vena cava injury | 41.37 | 21.12 | 10 | 8016 | 208 | 29566293 |
SARS-CoV-2 antibody test positive | 40.71 | 21.12 | 10 | 8016 | 223 | 29566278 |
Haematochezia | 40.43 | 21.12 | 50 | 7976 | 36933 | 29529568 |
Renal cyst haemorrhage | 39.78 | 21.12 | 11 | 8015 | 394 | 29566107 |
Gastrointestinal haemorrhage | 36.48 | 21.12 | 72 | 7954 | 79461 | 29487040 |
Fall | 35.42 | 21.12 | 117 | 7909 | 177061 | 29389440 |
Arrhythmia | 32.09 | 21.12 | 41 | 7985 | 31272 | 29535229 |
Renal failure | 31.89 | 21.12 | 87 | 7939 | 118512 | 29447989 |
Spontaneous haemorrhage | 31.85 | 21.12 | 8 | 8018 | 196 | 29566305 |
Dyspnoea exertional | 31.60 | 21.12 | 44 | 7982 | 36446 | 29530055 |
Gamma-glutamyltransferase increased | 30.59 | 21.12 | 37 | 7989 | 26700 | 29539801 |
JC virus CSF test positive | 30.34 | 21.12 | 7 | 8019 | 118 | 29566383 |
Language disorder | 29.10 | 21.12 | 13 | 8013 | 1946 | 29564555 |
Anaemia | 27.09 | 21.12 | 117 | 7909 | 200834 | 29365667 |
Spinal stenosis | 26.86 | 21.12 | 16 | 8010 | 4347 | 29562154 |
Carotid arteriosclerosis | 26.13 | 21.12 | 11 | 8015 | 1427 | 29565074 |
Urinary incontinence | 26.05 | 21.12 | 27 | 7999 | 16454 | 29550047 |
Drug interaction | 25.90 | 21.12 | 114 | 7912 | 197271 | 29369230 |
Implant site inflammation | 25.74 | 21.12 | 6 | 8020 | 106 | 29566395 |
Mean cell haemoglobin concentration | 25.43 | 21.12 | 5 | 8021 | 37 | 29566464 |
Abdominal wall haemorrhage | 25.36 | 21.12 | 7 | 8019 | 249 | 29566252 |
Soft tissue haemorrhage | 24.59 | 21.12 | 6 | 8020 | 130 | 29566371 |
Cognitive disorder | 24.43 | 21.12 | 31 | 7995 | 23468 | 29543033 |
Actinic keratosis | 23.61 | 21.12 | 14 | 8012 | 3772 | 29562729 |
Circulatory collapse | 23.27 | 21.12 | 27 | 7999 | 18646 | 29547855 |
Nail bed inflammation | 23.26 | 21.12 | 6 | 8020 | 164 | 29566337 |
Delayed graft function | 23.04 | 21.12 | 11 | 8015 | 1916 | 29564585 |
Orthostatic intolerance | 22.55 | 21.12 | 8 | 8018 | 654 | 29565847 |
Prothrombin level decreased | 22.30 | 21.12 | 9 | 8017 | 1049 | 29565452 |
Basophil count decreased | 21.63 | 21.12 | 5 | 8021 | 85 | 29566416 |
Nocturia | 21.56 | 21.12 | 18 | 8008 | 8344 | 29558157 |
Congestive hepatopathy | 21.15 | 21.12 | 10 | 8016 | 1704 | 29564797 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
General physical health deterioration | 375.14 | 19.80 | 314 | 12346 | 204111 | 64281961 |
Product prescribing error | 347.16 | 19.80 | 159 | 12501 | 35110 | 64450962 |
Product monitoring error | 211.39 | 19.80 | 67 | 12593 | 5387 | 64480685 |
Haematochezia | 125.40 | 19.80 | 104 | 12556 | 66269 | 64419803 |
International normalised ratio increased | 123.15 | 19.80 | 111 | 12549 | 79056 | 64407016 |
Haematoma | 114.43 | 19.80 | 85 | 12575 | 46165 | 64439907 |
Anaemia | 105.10 | 19.80 | 230 | 12430 | 378450 | 64107622 |
Drug ineffective | 93.54 | 19.80 | 25 | 12635 | 840222 | 63645850 |
Dizziness | 83.75 | 19.80 | 228 | 12432 | 429935 | 64056137 |
Cardiac failure | 82.36 | 19.80 | 115 | 12545 | 132258 | 64353814 |
Drug interaction | 80.76 | 19.80 | 202 | 12458 | 361881 | 64124191 |
Arrhythmia | 79.86 | 19.80 | 73 | 12587 | 52871 | 64433201 |
Syncope | 79.42 | 19.80 | 124 | 12536 | 157511 | 64328561 |
Atrial fibrillation | 78.56 | 19.80 | 129 | 12531 | 170960 | 64315112 |
Dyspnoea | 75.49 | 19.80 | 309 | 12351 | 718365 | 63767707 |
International normalised ratio abnormal | 73.68 | 19.80 | 30 | 12630 | 4958 | 64481114 |
Bradycardia | 70.99 | 19.80 | 101 | 12559 | 118118 | 64367954 |
Fall | 68.53 | 19.80 | 208 | 12452 | 416618 | 64069454 |
Electrolyte imbalance | 68.31 | 19.80 | 49 | 12611 | 25194 | 64460878 |
Gastrointestinal haemorrhage | 62.37 | 19.80 | 101 | 12559 | 132211 | 64353861 |
Labelled drug-drug interaction medication error | 53.31 | 19.80 | 40 | 12620 | 22022 | 64464050 |
Respiratory tract haemorrhage | 52.44 | 19.80 | 17 | 12643 | 1467 | 64484605 |
Spontaneous haemorrhage | 52.40 | 19.80 | 13 | 12647 | 423 | 64485649 |
Therapeutic drug monitoring analysis not performed | 51.58 | 19.80 | 16 | 12644 | 1196 | 64484876 |
Pallor | 49.92 | 19.80 | 49 | 12611 | 38732 | 64447340 |
Platelet dysfunction | 49.53 | 19.80 | 12 | 12648 | 353 | 64485719 |
Oedema peripheral | 48.51 | 19.80 | 119 | 12541 | 210198 | 64275874 |
Circulatory collapse | 44.12 | 19.80 | 43 | 12617 | 33689 | 64452383 |
Vena cava injury | 44.05 | 19.80 | 10 | 12650 | 220 | 64485852 |
Prothrombin time prolonged | 43.60 | 19.80 | 31 | 12629 | 15710 | 64470362 |
SARS-CoV-2 antibody test positive | 43.26 | 19.80 | 10 | 12650 | 239 | 64485833 |
Intestinal haemorrhage | 42.37 | 19.80 | 21 | 12639 | 5493 | 64480579 |
Arthralgia | 42.28 | 19.80 | 17 | 12643 | 442243 | 64043829 |
Renal cyst haemorrhage | 41.88 | 19.80 | 11 | 12649 | 451 | 64485621 |
Renal failure | 41.03 | 19.80 | 102 | 12558 | 181586 | 64304486 |
Intraductal papillary mucinous neoplasm | 39.08 | 19.80 | 11 | 12649 | 586 | 64485486 |
Blood loss anaemia | 37.65 | 19.80 | 27 | 12633 | 13865 | 64472207 |
Disorientation | 36.92 | 19.80 | 50 | 12610 | 55778 | 64430294 |
Language disorder | 35.59 | 19.80 | 15 | 12645 | 2702 | 64483370 |
Completed suicide | 33.06 | 19.80 | 3 | 12657 | 224411 | 64261661 |
Coagulation test abnormal | 32.27 | 19.80 | 11 | 12649 | 1108 | 64484964 |
Foetal chromosome abnormality | 32.19 | 19.80 | 5 | 12655 | 10 | 64486062 |
Actinic keratosis | 31.96 | 19.80 | 17 | 12643 | 5148 | 64480924 |
Right ventricular failure | 31.17 | 19.80 | 29 | 12631 | 21442 | 64464630 |
JC virus CSF test positive | 30.88 | 19.80 | 7 | 12653 | 153 | 64485919 |
Painful respiration | 30.60 | 19.80 | 14 | 12646 | 3067 | 64483005 |
Electrocardiogram abnormal | 29.40 | 19.80 | 23 | 12637 | 13458 | 64472614 |
Contraindicated product administered | 29.17 | 19.80 | 65 | 12595 | 107764 | 64378308 |
Dehydration | 29.00 | 19.80 | 101 | 12559 | 216662 | 64269410 |
Fracture | 28.53 | 19.80 | 26 | 12634 | 18729 | 64467343 |
Overdose | 28.34 | 19.80 | 82 | 12578 | 159484 | 64326588 |
Tachycardia | 27.67 | 19.80 | 78 | 12582 | 149501 | 64336571 |
Rectal prolapse | 27.63 | 19.80 | 11 | 12649 | 1715 | 64484357 |
Mean cell haemoglobin concentration | 27.55 | 19.80 | 5 | 12655 | 33 | 64486039 |
Gamma-glutamyltransferase increased | 26.97 | 19.80 | 40 | 12620 | 48470 | 64437602 |
Pulmonary vein occlusion | 26.48 | 19.80 | 6 | 12654 | 131 | 64485941 |
Aortic arteriosclerosis | 26.12 | 19.80 | 17 | 12643 | 7459 | 64478613 |
Blood glucose abnormal | 25.72 | 19.80 | 18 | 12642 | 8895 | 64477177 |
Carotid arteriosclerosis | 25.65 | 19.80 | 11 | 12649 | 2068 | 64484004 |
Prothrombin level decreased | 25.64 | 19.80 | 10 | 12650 | 1476 | 64484596 |
Presyncope | 25.62 | 19.80 | 33 | 12627 | 35056 | 64451016 |
Haematuria | 25.56 | 19.80 | 44 | 12616 | 60427 | 64425645 |
Prothrombin time shortened | 25.36 | 19.80 | 12 | 12648 | 2837 | 64483235 |
Eosinophilic granulomatosis with polyangiitis | 25.23 | 19.80 | 12 | 12648 | 2870 | 64483202 |
Rash | 25.05 | 19.80 | 32 | 12628 | 458517 | 64027555 |
Vitamin K deficiency | 24.89 | 19.80 | 8 | 12652 | 671 | 64485401 |
Spinal stenosis | 24.56 | 19.80 | 21 | 12639 | 13910 | 64472162 |
Blood glucose fluctuation | 24.46 | 19.80 | 15 | 12645 | 5940 | 64480132 |
Anxiety | 24.46 | 19.80 | 5 | 12655 | 202644 | 64283428 |
Epistaxis | 24.16 | 19.80 | 57 | 12603 | 98074 | 64387998 |
Abdominal wall haemorrhage | 24.09 | 19.80 | 7 | 12653 | 418 | 64485654 |
Drug intolerance | 24.06 | 19.80 | 4 | 12656 | 187988 | 64298084 |
Cardiorenal syndrome | 23.67 | 19.80 | 9 | 12651 | 1241 | 64484831 |
Implant site inflammation | 23.52 | 19.80 | 6 | 12654 | 219 | 64485853 |
Product dose omission issue | 23.10 | 19.80 | 5 | 12655 | 194742 | 64291330 |
Off label use | 22.99 | 19.80 | 57 | 12603 | 632749 | 63853323 |
Benign prostatic hyperplasia | 22.99 | 19.80 | 17 | 12643 | 9148 | 64476924 |
Dyspnoea exertional | 22.88 | 19.80 | 47 | 12613 | 73683 | 64412389 |
Melaena | 22.68 | 19.80 | 39 | 12621 | 53509 | 64432563 |
Headache | 22.25 | 19.80 | 44 | 12616 | 529423 | 63956649 |
Small intestine polyp | 22.23 | 19.80 | 4 | 12656 | 25 | 64486047 |
Febrile neutropenia | 21.89 | 19.80 | 5 | 12655 | 187652 | 64298420 |
Coagulopathy | 21.72 | 19.80 | 29 | 12631 | 31891 | 64454181 |
Delayed graft function | 21.67 | 19.80 | 11 | 12649 | 3025 | 64483047 |
Disturbance in attention | 21.60 | 19.80 | 33 | 12627 | 41041 | 64445031 |
Cerebral haemorrhage | 21.36 | 19.80 | 37 | 12623 | 51053 | 64435019 |
International normalised ratio decreased | 21.34 | 19.80 | 15 | 12645 | 7463 | 64478609 |
Accidental underdose | 21.04 | 19.80 | 7 | 12653 | 655 | 64485417 |
Abdominal discomfort | 20.98 | 19.80 | 5 | 12655 | 182317 | 64303755 |
Soft tissue haemorrhage | 20.87 | 19.80 | 6 | 12654 | 345 | 64485727 |
Urogenital haemorrhage | 20.85 | 19.80 | 7 | 12653 | 673 | 64485399 |
Hemiparesis | 20.15 | 19.80 | 27 | 12633 | 29800 | 64456272 |
Traumatic haemothorax | 20.10 | 19.80 | 6 | 12654 | 394 | 64485678 |
Nocturia | 20.03 | 19.80 | 17 | 12643 | 11148 | 64474924 |
Product use in unapproved indication | 20.02 | 19.80 | 5 | 12655 | 176613 | 64309459 |
Peripheral arterial occlusive disease | 19.90 | 19.80 | 14 | 12646 | 6973 | 64479099 |
Haemoptysis | 19.83 | 19.80 | 35 | 12625 | 49013 | 64437059 |
None
Source | Code | Description |
---|---|---|
ATC | B01AA04 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Vitamin K antagonists |
FDA EPC | N0000175476 | Vitamin K Antagonist |
MeSH PA | D000925 | Anticoagulants |
MeSH PA | D006401 | Hematologic Agents |
FDA MoA | N0000175964 | Vitamin K Inhibitors |
CHEBI has role | CHEBI:50249 | anticoagulants |
CHEBI has role | CHEBI:50390 | NAD(P)H dehydrogenase (quinone) inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Myocardial infarction | indication | 22298006 | DOID:5844 |
Thromboembolic disorder | indication | 371039008 | |
Thrombosis | indication | 439127006 | |
Prosthetic replacement of heart valve | off-label use | 307279007 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.51 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Vitamin K epoxide reductase complex subunit 1 | Enzyme | INHIBITOR | IC50 | 5.75 | SCIENTIFIC LITERATURE | CHEMBL | |||
Pol polyprotein | Enzyme | Ki | 6.10 | CHEMBL | |||||
Vitamin K epoxide reductase complex subunit 1 | Unclassified | Ki | 6.70 | CHEMBL |
ID | Source |
---|---|
4018525 | VUID |
N0000146847 | NUI |
D05457 | KEGG_DRUG |
4018525 | VANDF |
C0031444 | UMLSCUI |
CHEBI:50438 | CHEBI |
CHEMBL1465 | ChEMBL_ID |
CHEMBL16694 | ChEMBL_ID |
DB00946 | DRUGBANK_ID |
D010644 | MESH_DESCRIPTOR_UI |
54680692 | PUBCHEM_CID |
6839 | IUPHAR_LIGAND_ID |
247 | INN_ID |
Q08SIO485D | UNII |
8150 | RXNORM |
002086 | NDDF |
59488002 | SNOMEDCT_US |
None